Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | LTK | P29376 | 2/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789747 | 1.00 | PDK2 (0.52) | PDK2PDK4CREBBPBRPF1ALDH1A1 | |
| SCHEMBL18177174 | 0.89 | PDK2 (0.50) | PDK2PDK4CREBBPBRPF1ALDH1A1 | |
| SCHEMBL12237301 | 0.87 | PDK2 (0.53) | PDK2PDK4CREBBPBRPF1ALDH1A1 | |
| SCHEMBL14328387 | 0.84 | PDK2 (0.46) | PDK2PDK4CREBBPBRPF1ALDH1A1 | |
| SCHEMBL14964158 | 0.82 | PDK2 (0.44) | PDK2PDK4CREBBPBRPF1ALDH1A1 | |
| SCHEMBL9591821 | 0.78 | PDK2 (0.71) | PDK2PDK4CREBBPBRPF1ALDH1A1 | |
| SCHEMBL3594073 | 0.75 | MGAT2 (0.37) | PDK2PDK4ALDH1A1GAAMGAT2 | |
| SCHEMBL3596379 | 0.75 | MGAT2 (0.37) | PDK2PDK4ALDH1A1GAAMGAT2 | |
| SCHEMBL7170898 | 0.75 | CSNK1G1 (0.45) | CREBBPALDH1A1GAAACVR1MGAT2 | |
| SCHEMBL17586345 | 0.74 | PDK2 (0.41) | PDK2PDK4CREBBPALDH1A1MGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021183707-A2 | FUNGICIDAL HALOMETHYL KETONES AND HYDRATES AND THEIR MIXTURES | FMC CORPORATION (US) | 2021-09-16 | — | — | WO | disclosed |
| EP-3805215-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021055630-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL- BIOTECH INVESTMENTS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-4466916-A | LIGHT STABLE PLASTICIZERS | THE B. F. GOODRICH COMPANY (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0001284-B1 | UV-LIGHT STABILIZED COMPOSITIONS CONTAINING SUBSTITUTED 2-KETO-1,4-DIAZACYCLOALKANES | The B.F. GOODRICH Company (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4297497-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY | 1981-10-27 | — | — | US | disclosed |
| US-4292240-A | PHOTOSTABILIZERS FOR PLASTICS | THE B. F. GOODRICH COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| EP-0029088-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-05-27 | — | — | EP | disclosed |
| EP-0024337-A1 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1981-03-04 | — | — | EP | disclosed |
| US-4190571-A | POLYOLEFINS | THE B. F. GOODRICH COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4167512-A | Synthesis of 2-keto-1,4-diazacycloalkanes | THE B. F. GOODRICH COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| EP-0001559-A2 | Synthesis of 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-05-02 | — | — | EP | disclosed |
| EP-0001284-A1 | UV-light stabilized compositions containing substituted 2-keto-1,4-diazacycloalkanes | The B.F. GOODRICH Company (US) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | PDK2 2681/4885PDK4 2815/4885CREBBP 3500/4885 |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | CBR3, NOS3, CBR1 | PDK2 427/4885PDK4 619/4885CREBBP 3810/4885 |
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | PDK2 1632/4885PDK4 2091/4885CREBBP 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.